SLActive chemical surfaces promote dental bone integration

Dental implants have offered a successful way to restore teeth for more than 20 years. New challenges for improving the process include shortening the time to restore functionality and meeting aesthetic demands. Altering implant surfaces to help promote bone integration is one solution. SLActive, a new chemically-modified surface for titanium, the standard material of which implants are constructed, has shown positive results in this area.

An article in the August issue of the Journal of Oral Implantology reports a 98.2% success rate for SLActive at dental patients' one-year follow-up. A noninterventional study was conducted to compare these results with previous findings of high survival and success rates among the same type of implants in a controlled clinical trial.

In this noninterventional study, results were obtained under common dental practice conditions where patient selection was not restrictive and technique was not controlled. Thirty dental clinics in Italy participated, and 226 patients were treated. Patients presented with a variety of risk factors, and both early (48 hours to 3 months) and traditional (3 to 6 months) loading of the implant was performed.

Osseointegration—the connection between living bone and artificial implant—can determine stability of the implant over time. Surface properties of the titanium implant, such as topography and roughness, can assist the chemical and biological interface that occurs in the early stages of healing and thus influence the long-term outcome.

The 98.2% success rate of this study was similar to that reported in formal clinical trials. The high success rate in both studies shows that the SLActive implant surface can be safely used with consistent, predictable results. Patients can expect integration of their implants that restores functionality for chewing and speech as well as aesthetics.

Source : Journal of Oral Implantology

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Clinical trial finds pomalidomide effective for treating rare bleeding disorder